Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13441375 | 0.87 | PTGDR2 (0.61) | PTGDR2FFAR1FFAR4LTB4RLTB4R2 | |
| SCHEMBL3582455 | 0.83 | PTGDR2 (0.55) | PTGDR2LTB4RLTB4R2 | |
| SCHEMBL13407843 | 0.83 | GAA (0.55) | TBXAS1MAPTPPARGALDH1A1 | |
| SCHEMBL13442129 | 0.83 | TBXAS1 (0.46) | LTB4RLTB4R2TBXAS1MAPTPPARG | |
| SCHEMBL5109293 | 0.79 | PTGER1 (0.68) | — | |
| SCHEMBL13440809 | 0.78 | THRA (0.50) | PTGDR2FFAR1FFAR4LTB4RLTB4R2 | |
| SCHEMBL11566670 | 0.78 | MAPT (0.58) | TBXAS1MAPTLTA4H | |
| SCHEMBL11566931 | 0.78 | MAPT (0.58) | TBXAS1MAPTLTA4H | |
| SCHEMBL11362734 | 0.75 | KDM4E (0.59) | MAPTALDH1A1 | |
| SCHEMBL3583333 | 0.75 | TBXAS1 (0.43) | LTB4RLTB4R2TBXAS1MAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | METABOLEX, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-7622491-B2 | Type 2 diabetes, atherosclerosis, cardiovascular disease, Syndrome X; carboxylic acids with dialkyldiether or thioether linking groups e.g. {4-[3-(2-Benzotriazol-2-yl-4-chloro-phenoxy)-propoxy]-phenyl}-acetic acid and {4-[3-(2-benzotriazol-2-yl-4-thiophen-2-yl-phenoxy)-propoxy]-phenyl}-acetic acid | METABOLEX INC. (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087468-A1 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION | PPARG, PPARD, PPARA | PTGDR2 449/4885FFAR1 8/4885FFAR4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.